Report Date: Thursday, July 30, 2026, before market open | Event: 2026Q2 Earnings Call
Baxter enters tomorrow's print in the middle of a multi-year operational turnaround, with shares having rallied hard into the event. According to price data, BAX has climbed from roughly $16.78 on April 1, 2026 to $24.82 at the July 29 close — a nearly 50% run — with a particularly sharp leg higher in the last week of July. Baxter International Inc. is scheduled to release second-quarter 2026 results on July 30, before the opening bell.
Consensus is bracing for a soft print on a year-over-year basis: the consensus estimate for revenues is pegged at $2.84 billion, indicating a decline of 0.6% from the prior-year quarter's reported figure, while one sell-side model is more conservative, estimating total revenues from continuing operations to decline 2.5% at constant currency (cc) to $2.79 billion. On earnings, the consensus mark for earnings is pinned at 36 cents per share, implying a 39% year-over-year decline. For context, Baxter's earnings beat estimates in two of the trailing four quarters and missed twice, delivering an average surprise of 3.12%, and Q1 2026 itself beat comfortably — Baxter International reported $2.7 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.9%, and EPS of $0.36 for the same period compares to $0.55 a year ago, well above the consensus EPS estimate being $0.31.
Baxter reiterated full-year 2026 guidance at Q1 — reported sales growth of flat to 1%, organic sales roughly flat, and adjusted EPS of $1.85–$2.05 — and management explicitly framed 2026 as a "known headwinds in H1, improvement in H2" year. On the Q1 call, management guided that Q2 would look similar to Q1, with only slight sequential volume improvement, because absorption-related manufacturing cost headwinds in the Infusion Therapies & Technologies business were expected to be "more pronounced" in Q2 before rolling off in the back half. Management laid out a specific bridge for the ~500bps of expected H1-to-H2 operating margin expansion: roughly half from normal seasonal volume/leverage, a quarter from cost-structure actions taken earlier in the year, and a quarter from working through higher-cost inventory produced in late 2025.
Free cash flow was a bright spot in Q1 ($76M vs. -$221M in Q1 2025), and management continues to target net leverage of approximately 3x by year-end 2026 as the top capital-allocation priority, ahead of any dividend restoration or buybacks.
Investors should note that Q2 2026 is the first quarter reported under Baxter's new two-segment structure. Per an 8-K filed July 14, 2026, Baxter collapsed its former three-segment model (Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals) into two segments: the former Pharmaceuticals business (Injectables & Anesthesia, Drug Compounding) is now folded into an expanded MPT segment as the "Infusion Therapies & Platforms" division, while HST is unchanged. Baxter also revised its corporate cost-allocation methodology so that certain shared corporate expenses now stay unallocated rather than being pushed down into segment operating income. This doesn't change consolidated results, but it will make headline segment margins harder to compare directly to pre-2026 prints — expect the earnings deck to lean heavily on the recast historical tables Baxter already furnished to bridge the transition.
1. Novum IQ LVP pump — still on ice. The voluntary shipment/installation hold on the Novum IQ large-volume infusion pump has been in place through Q1, and guidance assumes it remains in place for the full year. Management has repeatedly flagged the risk of customer returns/exchanges to competing platforms (Spectrum) as a guidance risk it has "not seen material impact from" yet — any change in tone here (either confirmation of continued benign trends, or signs of accelerating switching) will be a key data point, alongside any update on timing for hardware/software corrective submissions to regulators.
2. Injectables & Anesthesia supply recovery. This sub-business has been the weakest link, pressured by a contract-manufacturer disruption and a manufacturing back-order issue that management said it made "significant progress" clearing in Q1. Baxter has signaled it expects limited supply into 2027 for some of the affected products, so the pace of recovery here is a multi-quarter overhang, offset partially by continued strong Drug Compounding growth (+20% organic in Q1).
3. HST order book and new product ramp. Growth in Healthcare Systems & Technologies is guided to be back-half weighted, driven by the ramp of newly launched Connex 360 monitoring platform and the Dynamo smart stretcher, plus normalization in Front Line Care after Q1 order-timing noise. Commentary on the CCS capital order book (management has said it hasn't seen a U.S. hospital capex slowdown) will be watched closely given macro uncertainty.
4. Tariffs and input costs. Full-year guidance embeds an ~$80M net tariff impact (~$40M year-over-year headwind). Any incremental commentary on oil/freight/chip costs, especially given commodity moves since the Q1 call, matters for gross margin trajectory.
5. Quality/regulatory overhang — Volara recall. Baxter Healthcare recently initiated a voluntary FDA Class I recall of its Hillrom VOLARA System single-patient-use circuit kits, after reports that nebulizer cup leakage could cause oxygen level drops and ineffective treatment, with seven serious injuries and no deaths related to this issue between May 30, 2022, and March 24, 2026 per FDA data. Commentary suggests the Class I VOLARA circuit recall spotlights quality control and regulatory risk in its devices segment, but based on what we know today, it does not appear to fundamentally alter the near term focus on margin repair and execution — still, expect analysts to press for reassurance that this is contained and unrelated to the broader Novum quality narrative.
6. CFO search. Anita Zielinski has been serving as interim CFO (also Chief Accounting Officer/Controller) since Joel Grade's departure was announced in March 2026, with the search for a permanent CFO ongoing. Any update on timing would reduce a lingering leadership-uncertainty overhang.
Sell-side sentiment has been notably split but has skewed more constructive in recent weeks even as fundamentals stay pressured. In July alone, TD Cowen raised its target to $24 from $20, Goldman Sachs to $21, Evercore ISI to $24, and UBS initiated at Neutral with a $25 target — while Citigroup has maintained a Sell rating. Ahead of the print, there has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 4.4% on average over the last month, and Baxter is up 11.3% during the same time, heading into earnings with an average analyst price target of $22.96 compared to the current share price of $24.50 — meaning the stock has effectively run ahead of consensus price targets into the print, raising the bar for a positive reaction.
On the full-year picture, analysts expect BAX to report EPS of $1.92, down 15.4% from $2.27 in fiscal 2025, while its EPS is expected to rise 2.1% year over year to $1.96 in fiscal 2027 — consistent with management's own framing of 2026 as a trough/reset year with modest growth resuming in 2027 as TSAs roll off and cost actions fully annualize.
This is a "show-me" quarter for a company in year two of a CEO-led turnaround (Andrew Hider) built around the "Baxter GPS" continuous-improvement program, balance-sheet deleveraging, and stabilization of a business still absorbing the Novum pump hold, a reset IV-fluids demand baseline, and pharma supply constraints. The bar is low on headline EPS (~$0.36, down ~39% y/y) and revenue (~flat to slightly down), but the stock's sharp pre-earnings rally means the market may already be pricing in confirmation of the back-half-loaded recovery story management has been selling since Q4 2025. Key things that would matter more than the headline beat/miss: (1) reaffirmation (or acceleration) of the H2 margin bridge, (2) any incremental Novum return/exchange data, (3) early read on HST order momentum and new-product contribution, and (4) progress/timeline on the CFO search and leverage path to 3x by year-end.